Detail
| LncRNA Name | FOXD2-AS1 |
| Synonyms | NA |
| Region | GRCh38_1:47432133-47434641 Sequence |
| Ensembl | ENSG00000237424 |
| RefSeq | NR_026878 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | cell line (T24) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA FOXD2-AS1 was high-expressed in gemcitabine-resistant bladder cancer cells. In vitro experiments, FOXD2-AS1 knockdown suppressed the 50% inhibitive concentration (IC50) of gemcitabine, drug-resistance related genes (MDR1, MRP2, LRP1) expression,invasion and ABCC3 protein expression in gemcitabine-resistant bladder cancer cells (T24/GEM, 5637/GEM). In vivo of xenograft assay, FOXD2-AS1 knockdown inhibited the tumor growth of bladder cancer cells.Bioinformatics program and validation experiments confirmed that FOXD2-AS1 positively regulated ABCC3 protein through targeting miR-143,acting as a competing endogenous RNA (ceRNA).In summary,the vital roles of FOXD2-AS1/miR-143/ABCC3 axis in gemcitabine resistance of bladder cancer cells, providing a novel therapeutic strategy for bladder cancer. We found that lncRNA FOXD2-AS1 sponged miR-143 to indirectly target ABCC3 protein ex- pression, consisting the FOXD2-AS1/miR-143/ABCC3 axis. |
| Pubmed ID | 29674277 |
| Year | 2018 |
| Title | Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. |
| External Links |
| Links for FOXD2-AS1 | GenBank HGNC lncrnadb Noncode |
| Links for bladder cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.